Optimizing stem cells for cardiac repair: Current status and new frontiers in regenerative cardiology

World Journal of Stem Cells

Volumn 9, Issue 1, 2017, Pages 9-25

  Sarkissian, Shant Der ^a   Lévesque, Thierry ^a   Noiseux, Nicolas ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cellular cardiomyoplasty; Heart failure; Myocardial infarction; Paracrine activity; Pharmaco optimizer; Preconditioning; Regenerative medicine; Stem cell; Transplantation; Viability

Indexed keywords

ANGIOGENESIS; CARDIAC MUSCLE CELL; CELL DEATH; CELL DIFFERENTIATION; CELL POPULATION; CELL SURVIVAL; CELL THERAPY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DNA MODIFICATION; EX VIVO STUDY; GENE TARGETING; HEART FUNCTION; HEART SURGERY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE RESPONSE; ISCHEMIC HEART DISEASE; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REGENERATIVE MEDICINE; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION;

EID: 85030165876     PISSN: None     EISSN: 19480210     Source Type: Journal    
DOI: 10.4252/wjsc.v9.i1.9     Document Type: Review

References (263)

1. Chiu RC, Zibaitis A, Kao RL. Cellular cardiomyoplasty: myocardial regeneration with satellite cell implantation. Ann Thorac Surg 1995; 60: 12-18 [PMID: 7598572]
2. Li RK, Jia ZQ, Weisel RD, Mickle DA, Zhang J, Mohabeer MK, Rao V, Ivanov J. Cardiomyocyte transplantation improves heart function. Ann Thorac Surg 1996; 62: 654-660; discussion 660-661 [PMID: 8783989]
3. Scorsin M, Hagege AA, Dolizy I, Marotte F, Mirochnik N, Copin H, Barnoux M, le Bert M, Samuel JL, Rappaport L, Menasché P. Can cellular transplantation improve function in doxorubicin-induced heart failure? Circulation 1998; 98: II151-II155; discussion II155-II156 [PMID: 9852897]
4. Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, Watt SM. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J 2008; 29: 1807-1818 [PMID: 18523058 DOI: 10.1093/eurheartj/ehn220]
5. Fisher SA, Doree C, Mathur A, Martin-Rendon E. Meta-analysis of cell therapy trials for patients with heart failure. Circ Res 2015; 116: 1361-1377 [PMID: 25632038 DOI: 10.1161/CIRCRE-SAHA.116.304386]
6. Mills JS, Rao SV. REPAIR-AMI: stem cells for acute myocardial infarction. Future Cardiol 2007; 3: 137-140 [PMID: 19804241 DOI: 10.2217/14796678.3.2.137]
7. Drexler H, Meyer GP, Wollert KC. Bone-marrow-derived cell transfer after ST-elevation myocardial infarction: lessons from the BOOST trial. Nat Clin Pract Cardiovasc Med 2006; 3 Suppl 1: S65-S68 [PMID: 16501634 DOI: 10.1038/ncpcardio0407]
8. Rangappa S, Makkar R, Forrester J. Review article: current status of myocardial regeneration: new cell sources and new strategies. J Cardiovasc Pharmacol Ther 2010; 15: 338-343 [PMID: 21098418 DOI: 10.1177/1074248410376382]
9. Yousef M, Schannwell CM, Köstering M, Zeus T, Brehm M, Strauer BE. The BALANCE Study: clinical benefit and longterm outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. J Am Coll Cardiol 2009; 53: 2262-2269 [PMID: 19520249 DOI: 10.1016/j.jacc.2009.02.051]
10. Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet W, Kalantzi M, Herbots L, Sinnaeve P, Dens J, Maertens J, Rademakers F, Dymarkowski S, Gheysens O, Van Cleemput J, Bormans G, Nuyts J, Belmans A, Mortelmans L, Boogaerts M, Van de Werf F. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: doubleblind, randomised controlled trial. Lancet 2006; 367: 113-121 [PMID: 16413875 DOI: 10.1016/S0140-6736(05)67861-0]
11. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008; 103: 1204-1219 [PMID: 19028920 DOI: 10.1161/CIRCRESAHA.108.176826]
12. Shabbir A, Zisa D, Suzuki G, Lee T. Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen. Am J Physiol Heart Circ Physiol 2009; 296: H1888-H1897 [PMID: 19395555 DOI: 10.1152/ ajpheart.00186.2009]
13. Lin H, Shabbir A, Molnar M, Yang J, Marion S, Canty JM, Lee T. Adenoviral expression of vascular endothelial growth factor splice variants differentially regulate bone marrow-derived mesenchymal stem cells. J Cell Physiol 2008; 216: 458-468 [PMID: 18288639 DOI: 10.1002/jcp.21414]
14. Ziegelhoeffer T, Fernandez B, Kostin S, Heil M, Voswinckel R, Helisch A, Schaper W. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ Res 2004; 94: 230-238 [PMID: 14656934 DOI: 10.1161/01.RES.0000110419.50982.1C]
15. Pourrajab F, Babaei Zarch M, Baghi Yazdi M, Rahimi Zarchi A, Vakili Zarch A. Application of stem cell/growth factor system, as a multimodal therapy approach in regenerative medicine to improve cell therapy yields. Int J Cardiol 2014; 173: 12-19 [PMID: 24612559 DOI: 10.1016/j.ijcard.2014.02.006]
16. Wollert KC, Drexler H. Cell therapy for the treatment of coronary heart disease: a critical appraisal. Nat Rev Cardiol 2010; 7: 204-215 [PMID: 20177405 DOI: 10.1038/nrcardio.2010.1]
17. Xu C. Differentiation and enrichment of cardiomyocytes from human pluripotent stem cells. J Mol Cell Cardiol 2012; 52: 1203-1212 [PMID: 22484618 DOI: 10.1016/j.yjmcc.2012.03.012]
18. Melo LG, Pachori AS, Kong D, Gnecchi M, Wang K, Pratt RE, Dzau VJ. Molecular and cell-based therapies for protection, rescue, and repair of ischemic myocardium: reasons for cautious optimism. Circulation 2004; 109: 2386-2393 [PMID: 15159329 DOI: 10.1161/01.CIR.0000128597.37025.00]
19. Vertesaljai M, Piroth Z, Fontos G, Andreka G, Font G, Szantho G, Lueff S, Reti M, Masszi T, Ablonczy L, Juhasz ED, Simor T, Turner MS, Andreka P. Drugs, gene transfer, signaling factors: a bench to bedside approach to myocardial stem cell therapy. Heart Fail Rev 2008; 13: 227-244 [PMID: 17668319 DOI: 10.1007/ s10741-007-9047-9]
20. Laflamme MA, Murry CE. Regenerating the heart. Nat Biotechnol 2005; 23: 845-856 [PMID: 16003373 DOI: 10.1038/nbt1117]
21. Chen L, Tredget EE, Wu PY, Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 2008; 3: e1886 [PMID: 18382669 DOI: 10.1371/journal.pone.0001886]
22. Luttun A, Carmeliet P. De novo vasculogenesis in the heart. Cardiovasc Res 2003; 58: 378-389 [PMID: 12757872]
23. Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol 2004; 287: C572-C579 [PMID: 15308462 DOI: 10.1152/ajpcell.00330.2003]
24. Smith RR, Barile L, Cho HC, Leppo MK, Hare JM, Messina E, Giacomello A, Abraham MR, Marbán E. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 2007; 115: 896-908 [PMID: 17283259 DOI: 10.1161/CIRCULATIONAHA.106.655209]
25. Murry CE, Field LJ, Menasché P. Cell-based cardiac repair: reflections at the 10-year point. Circulation 2005; 112: 3174-3183 [PMID: 16286608 DOI: 10.1161/CIRCULATIONAHA.105.546218]
26. Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J 2007; 28: 766-772 [PMID: 17298974 DOI: 10.1093/eurheartj/ehl509]
27. Kumar S, Chanda D, Ponnazhagan S. Therapeutic potential of genetically modified mesenchymal stem cells. Gene Ther 2008; 15: 711-715 [PMID: 18356815 DOI: 10.1038/gt.2008.35]
28. Graf T. Differentiation plasticity of hematopoietic cells. Blood 2002; 99: 3089-3101 [PMID: 11964270]
29. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42-48 [PMID: 11823036]
30. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, Dzau VJ. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003; 9: 1195-1201 [PMID: 12910262 DOI: 10.1038/nm912]
31. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002; 105: 93-98 [PMID: 11772882]
32. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, Sano M, Takahashi T, Hori S, Abe H, Hata J, Umezawa A, Ogawa S. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999; 103: 697-705 [PMID: 10074487 DOI: 10.1172/JCI5298]
33. Schuleri KH, Boyle AJ, Hare JM. Mesenchymal stem cells for cardiac regenerative therapy. Handb Exp Pharmacol 2007; (180): 195-218 [PMID: 17554510 DOI: 10.1007/978-3-540-68976-8_9]
34. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410: 701-705 [PMID: 11287958 DOI: 10.1038/35070587]
35. Heldman AW, Di Fede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, Mushtaq M, Williams AR, Suncion VY, McNiece IK, Ghersin E, Soto V, Lopera G, Miki R, Willens H, Hendel R, Mitrani R, Pattany P, Feigenbaum G, Oskouei B, Byrnes J, Lowery MH, Sierra J, Pujol MV, Delgado C, Gonzalez PJ, Rodriguez JE, Bagno LL, Rouy D, Altman P, Foo CW, da Silva J, Anderson E, Schwarz R, Mendizabal A, Hare JM. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA 2014; 311: 62-73 [PMID: 24247587 DOI: 10.1001/ jama.2013.282909]
36. Chen S, Liu Z, Tian N, Zhang J, Yei F, Duan B, Zhu Z, Lin S, Kwan TW. Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. J Invasive Cardiol 2006; 18: 552-556 [PMID: 17090821]
37. Shake JG, Gruber PJ, Baumgartner WA, Senechal G, Meyers J, Redmond JM, Pittenger MF, Martin BJ. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg 2002; 73: 1919-1225; discussion 1926 [PMID: 12078791]
38. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao LM, Lin S, Sun JP. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004; 94: 92-95 [PMID: 15219514 DOI: 10.1016/j.amjcard.2004.03.034]
39. Katritsis DG, Sotiropoulou PA, Karvouni E, Karabinos I, Korovesis S, Perez SA, Voridis EM, Papamichail M. Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc Interv 2005; 65: 321-329 [PMID: 15954106 DOI: 10.1002/ccd.20406]
40. Freyman T, Polin G, Osman H, Crary J, Lu M, Cheng L, Palasis M, Wilensky RL. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 2006; 27: 1114-1122 [PMID: 16510464 DOI: 10.1093/eurheartj/ehi818]
41. Sadek HA, Martin CM, Latif SS, Garry MG, Garry DJ. Bonemarrow-derived side population cells for myocardial regeneration. J Cardiovasc Transl Res 2009; 2: 173-181 [PMID: 20559985 DOI: 10.1007/s12265-009-9090-0]
42. Nakamura Y, Yasuda T, Weisel RD, Li RK. Enhanced cell transplantation: preventing apoptosis increases cell survival and ventricular function. Am J Physiol Heart Circ Physiol 2006; 291: H939-H947 [PMID: 16582022 DOI: 10.1152/ajpheart.00155.2006]
43. Suzuki K, Murtuza B, Beauchamp JR, Smolenski RT, Varela-Carver A, Fukushima S, Coppen SR, Partridge TA, Yacoub MH. Dynamics and mediators of acute graft attrition after myoblast transplantation to the heart. FASEB J 2004; 18: 1153-1155 [PMID: 15155562 DOI: 10.1096/fj.03-1308fje]
44. Gehling UM, Ergün S, Schumacher U, Wagener C, Pantel K, Otte M, Schuch G, Schafhausen P, Mende T, Kilic N, Kluge K, Schäfer B, Hossfeld DK, Fiedler W. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000; 95: 3106-3112 [PMID: 10807776]
45. Donndorf P, Useini D, Lux CA, Vollmar B, Delyagina E, Laupheimer M, Kaminski A, Steinhoff G. Analyzing migratory properties of human CD133(+) stem cells in vivo after intraoperative sternal bone marrow isolation. Cell Transplant 2013; 22: 1627-1635 [PMID: 23051098 DOI: 10.3727/096368912X657729]
46. Zhang Y, Wong S, Laflèche J, Crowe S, Mesana TG, Suuronen EJ, Ruel M. In vitro functional comparison of therapeutically relevant human vasculogenic progenitor cells used for cardiac cell therapy. J Thorac Cardiovasc Surg 2010; 140: 216-224, 224.e1-e4 [PMID: 20167338 DOI: 10.1016/j.jtcvs.2009.11.016]
47. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000; 95: 952-958 [PMID: 10648408]
48. Suuronen EJ, Veinot JP, Wong S, Kapila V, Price J, Griffith M, Mesana TG, Ruel M. Tissue-engineered injectable collagen-based matrices for improved cell delivery and vascularization of ischemic tissue using CD133+ progenitors expanded from the peripheral blood. Circulation 2006; 114: I138-I144 [PMID: 16820563 DOI: 10.1161/CIRCULATIONAHA.105.001081]
49. Senegaglia AC, Brofman PR, Aita CA, Dallagiovanna B, Rebelatto CL, Hansen P, Barchiki F, Krieger MA. In vitro formation of capillary tubules from human umbilical cord blood cells with perspectives for therapeutic application. Rev Bras Cir Cardiovasc 2008; 23: 467-473 [PMID: 19229416]
50. Ma N, Ladilov Y, Moebius JM, Ong L, Piechaczek C, Dávid A, Kaminski A, Choi YH, Li W, Egger D, Stamm C, Steinhoff G. Intramyocardial delivery of human CD133+ cells in a SCID mouse cryoinjury model: Bone marrow vs. cord blood-derived cells. Cardiovasc Res 2006; 71: 158-169 [PMID: 16730684 DOI: 10.1016/j.cardiores.2006.03.020]
51. Bonanno G, Mariotti A, Procoli A, Corallo M, Rutella S, Pessina G, Scambia G, Mancuso S, Pierelli L. Human cord blood CD133+ cells immunoselected by a clinical-grade apparatus differentiate in vitro into endothelial and cardiomyocyte-like cells. Transfusion 2007; 47: 280-289 [PMID: 17302775 DOI: 10.1111/j.1537-2995.2007.01104.x]
52. Forcillo J, Stevens LM, Mansour S, Prieto I, Salem R, Baron C, Roy DC, Larose E, Masckauchan D, Noiseux N. Implantation of CD133+ stem cells in patients undergoing coronary bypass surgery: IMPACT-CABG pilot trial. Can J Cardiol 2013; 29: 441-447 [PMID: 23265095 DOI: 10.1016/j.cjca.2012.08.009]
53. Forcillo J, Stevens LM, Mansour S, Prieto I, Roy DC, Noiseux N. IMPACT-CABG Trial: Implantation of CD133(+) Stem Cells in Patients Undergoing Coronary Bypass Surgery-Presentation of the First Treated Patient. Case Rep Transplant 2011; 2011: 685394 [PMID: 23213603 DOI: 10.1155/2011/685394]
54. Mansour S, Roy DC, Bouchard V, Stevens LM, Gobeil F, Rivard A, Leclerc G, Reeves F, Noiseux N. One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133 Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction. Bone Marrow Res 2011; 2011: 385124 [PMID: 22046562 DOI: 10.1155/2011/385124]
55. Mansour S, Roy DC, Bouchard V, Nguyen BK, Stevens LM, Gobeil F, Rivard A, Leclerc G, Reeves F, Noiseux N. COMPARE-AMI trial: comparison of intracoronary injection of CD133+ bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction: study rationale and design. J Cardiovasc Transl Res 2010; 3: 153-159 [PMID: 20560029 DOI: 10.1007/s12265-009-9145-2]
56. Mansour S, Roy DC, Lemieux B, Ouellet C, Stevens LM, Noiseux N. Stem cell therapy for the broken heart: mini-organ transplantation. Transplant Proc 2009; 41: 3353-3357 [PMID: 19857748 DOI: 10.1016/j.transproceed.2009.08.033]
57. Pagani FD, DerSimonian H, Zawadzka A, Wetzel K, Edge AS, Jacoby DB, Dinsmore JH, Wright S, Aretz TH, Eisen HJ, Aaronson KD. Autologous skeletal myoblasts transplanted to ischemiadamaged myocardium in humans. Histological analysis of cell survival and differentiation. J Am Coll Cardiol 2003; 41: 879-888 [PMID: 12628737]
58. Müller-Ehmsen J, Whittaker P, Kloner RA, Dow JS, Sakoda T, Long TI, Laird PW, Kedes L. Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J Mol Cell Cardiol 2002; 34: 107-116 [PMID: 11851351 DOI: 10.1006/ jmcc.2001.1491]
59. Shi RZ, Li QP. Improving outcome of transplanted mesenchymal stem cells for ischemic heart disease. Biochem Biophys Res Commun 2008; 376: 247-250 [PMID: 18789897 DOI: 10.1016/j.bbrc.2008.09.004]
60. Hofmann M, Wollert KC, Meyer GP, Menke A, Arseniev L, Hertenstein B, Ganser A, Knapp WH, Drexler H. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 2005; 111: 2198-2202 [PMID: 15851598 DOI: 10.1161/01.CIR.0000163546.27639.AA]
61. Goussetis E, Manginas A, Koutelou M, Peristeri I, Theodosaki M, Kollaros N, Leontiadis E, Theodorakos A, Paterakis G, Karatasakis G, Cokkinos DV, Graphakos S. Intracoronary infusion of CD133+ and CD133-CD34+ selected autologous bone marrow progenitor cells in patients with chronic ischemic cardiomyopathy: cell isolation, adherence to the infarcted area, and body distribution. Stem Cells 2006; 24: 2279-2283 [PMID: 16794269 DOI: 10.1634/ stemcells.2005-0589]
62. Schächinger V, Aicher A, Döbert N, Röver R, Diener J, Fichtlscherer S, Assmus B, Seeger FH, Menzel C, Brenner W, Dimmeler S, Zeiher AM. Pilot trial on determinants of progenitor cell recruitment to the infarcted human myocardium. Circulation 2008; 118: 1425-1432 [PMID: 18794392 DOI: 10.1161/ CIRCULATIONAHA.108.777102]
63. Blocklet D, Toungouz M, Berkenboom G, Lambermont M, Unger P, Preumont N, Stoupel E, Egrise D, Degaute JP, Goldman M, Goldman S. Myocardial homing of nonmobilized peripheral-blood CD34+ cells after intracoronary injection. Stem Cells 2006; 24: 333-336 [PMID: 16223854 DOI: 10.1634/stemcells.2005-0201]
64. Kang WJ, Kang HJ, Kim HS, Chung JK, Lee MC, Lee DS. Tissue distribution of 18F-FDG-labeled peripheral hematopoietic stem cells after intracoronary administration in patients with myocardial infarction. J Nucl Med 2006; 47: 1295-1301 [PMID: 16883008]
65. Tossios P, Krausgrill B, Schmidt M, Fischer T, Halbach M, Fries JW, Fahnenstich S, Frommolt P, Heppelmann I, Schmidt A, Schomäcker K, Fischer JH, Bloch W, Mehlhorn U, Schwinger RH, Müller-Ehmsen J. Role of balloon occlusion for mononuclear bone marrow cell deposition after intracoronary injection in pigs with reperfused myocardial infarction. Eur Heart J 2008; 29: 1911-1921 [PMID: 18544545 DOI: 10.1093/eurheartj/ehn218]
66. Hou D, Youssef EA, Brinton TJ, Zhang P, Rogers P, Price ET, Yeung AC, Johnstone BH, Yock PG, March KL. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation 2005; 112: I150-I156 [PMID: 16159808 DOI: 10.1161/CIRCULATIONAHA.104.526749]
67. Leiker M, Suzuki G, Iyer VS, Canty JM, Lee T. Assessment of a nuclear affinity labeling method for tracking implanted mesenchymal stem cells. Cell Transplant 2008; 17: 911-922 [PMID: 19069634]
68. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE. Cardiomyocyte grafting for cardiac repair: graft cell death and antideath strategies. J Mol Cell Cardiol 2001; 33: 907-921 [PMID: 11343414 DOI: 10.1006/jmcc.2001.1367]
69. Hodgetts SI, Beilharz MW, Scalzo AA, Grounds MD. Why do cultured transplanted myoblasts die in vivo? DNA quantification shows enhanced survival of donor male myoblasts in host mice depleted of CD4+ and CD8+ cells or Nk1.1+ cells. Cell Transplant 2000; 9: 489-502 [PMID: 11038066]
70. Mylotte LA, Duffy AM, Murphy M, O'Brien T, Samali A, Barry F, Szegezdi E. Metabolic flexibility permits mesenchymal stem cell survival in an ischemic environment. Stem Cells 2008; 26: 1325-1336 [PMID: 18308942 DOI: 10.1634/stemcells.2007-1072]
71. Chiarugi P, Giannoni E. Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol 2008; 76: 1352-1364 [PMID: 18708031 DOI: 10.1016/j.bcp.2008.07.023]
72. Michel JB. Anoikis in the cardiovascular system: known and unknown extracellular mediators. Arterioscler Thromb Vasc Biol 2003; 23: 2146-2154 [PMID: 14551156 DOI: 10.1161/01. ATV.0000099882.52647.E4]
73. Ingber DE. Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology. Circ Res 2002; 91: 877-887 [PMID: 12433832]
74. Guo J, Lin GS, Bao CY, Hu ZM, Hu MY. Anti-inflammation role for mesenchymal stem cells transplantation in myocardial infarction. Inflammation 2007; 30: 97-104 [PMID: 17497204 DOI: 10.1007/s10753-007-9025-3]
75. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999; 341: 738-746 [PMID: 10471461 DOI: 10.1056/ NEJM199909023411006]
76. Frangogiannis NG. Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem 2006; 13: 1877-1893 [PMID: 16842199]
77. Sáenz-Morales D, Conde E, Escribese MM, García-Martos M, Alegre L, Blanco-Sánchez I, García-Bermejo ML. ERK1/2 mediates cytoskeleton and focal adhesion impairment in proximal epithelial cells after renal ischemia. Cell Physiol Biochem 2009; 23: 285-294 [PMID: 19471096 DOI: 10.1159/000218175]
78. Zhu WG, Li S, Lin LQ, Yan H, Fu T, Zhu JH. Vascular oxidative stress increases dendritic cell adhesion and transmigration induced by homocysteine. Cell Immunol 2009; 254: 110-116 [PMID: 18809175 DOI: 10.1016/j.cellimm.2008.08.001]
79. Pelegrin P, Surprenant A. Dynamics of macrophage polarization reveal new mechanism to inhibit IL-1beta release through pyrophosphates. EMBO J 2009; 28: 2114-2127 [PMID: 19536133 DOI: 10.1038/emboj.2009.163]
80. Baraniak PR, McDevitt TC. Stem cell paracrine actions and tissue regeneration. Regen Med 2010; 5: 121-143 [PMID: 20017699 DOI: 10.2217/rme.09.74]
81. Noiseux N, Gnecchi M, Lopez-Ilasaca M, Zhang L, Solomon SD, Deb A, Dzau VJ, Pratt RE. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther 2006; 14: 840-850 [PMID: 16965940 DOI: 10.1016/ j.ymthe.2006.05.016]
82. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, Pasumarthi KB, Virag JI, Bartelmez SH, Poppa V, Bradford G, Dowell JD, Williams DA, Field LJ. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004; 428: 664-668 [PMID: 15034593 DOI: 10.1038/nature02446]
83. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 2004; 428: 668-673 [PMID: 15034594 DOI: 10.1038/nature02460]
84. Perez-Ilzarbe M, Agbulut O, Pelacho B, Ciorba C, San Jose-Eneriz E, Desnos M, Hagège AA, Aranda P, Andreu EJ, Menasché P, Prósper F. Characterization of the paracrine effects of human skeletal myoblasts transplanted in infarcted myocardium. Eur J Heart Fail 2008; 10: 1065-1072 [PMID: 18805052 DOI: 10.1016/ j.ejheart.2008.08.002]
85. Korf-Klingebiel M, Kempf T, Sauer T, Brinkmann E, Fischer P, Meyer GP, Ganser A, Drexler H, Wollert KC. Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. Eur Heart J 2008; 29: 2851-2858 [PMID: 18953051 DOI: 10.1093/eurheartj/ehn456]
86. Kubal C, Sheth K, Nadal-Ginard B, Galiñanes M. Bone marrow cells have a potent anti-ischemic effect against myocardial cell death in humans. J Thorac Cardiovasc Surg 2006; 132: 1112-1118 [PMID: 17059931 DOI: 10.1016/j.jtcvs.2006.06.028]
87. Xu M, Uemura R, Dai Y, Wang Y, Pasha Z, Ashraf M. In vitro and in vivo effects of bone marrow stem cells on cardiac structure and function. J Mol Cell Cardiol 2007; 42: 441-448 [PMID: 17187821 DOI: 10.1016/j.yjmcc.2006.10.009]
88. Uemura R, Xu M, Ahmad N, Ashraf M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 2006; 98: 1414-1421 [PMID: 16690882 DOI: 10.1161/01.RES.0000225952.61196.39]
89. Takahashi M, Li TS, Suzuki R, Kobayashi T, Ito H, Ikeda Y, Matsuzaki M, Hamano K. Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. Am J Physiol Heart Circ Physiol 2006; 291: H886-H893 [PMID: 16603697 DOI: 10.1152/ajpheart.00142.2006]
90. Liu CH, Hwang SM. Cytokine interactions in mesenchymal stem cells from cord blood. Cytokine 2005; 32: 270-279 [PMID: 16377203 DOI: 10.1016/j.cyto.2005.11.003]
91. Schinköthe T, Bloch W, Schmidt A. In vitro secreting profile of human mesenchymal stem cells. Stem Cells Dev 2008; 17: 199-206 [PMID: 18208373 DOI: 10.1089/scd.2007.0175]
92. Sarojini H, Estrada R, Lu H, Dekova S, Lee MJ, Gray RD, Wang E. PEDF from mouse mesenchymal stem cell secretome attracts fibroblasts. J Cell Biochem 2008; 104: 1793-1802 [PMID: 18348263 DOI: 10.1002/jcb.21748]
93. Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol 2009; 217: 318-324 [PMID: 19023885 DOI: 10.1002/ path.2469]
94. Kilroy GE, Foster SJ, Wu X, Ruiz J, Sherwood S, Heifetz A, Ludlow JW, Stricker DM, Potiny S, Green P, Halvorsen YD, Cheatham B, Storms RW, Gimble JM. Cytokine profile of human adiposederived stem cells: expression of angiogenic, hematopoietic, and proinflammatory factors. J Cell Physiol 2007; 212: 702-709 [PMID: 17477371 DOI: 10.1002/jcp.21068]
95. Pallante BA, Duignan I, Okin D, Chin A, Bressan MC, Mikawa T, Edelberg JM. Bone marrow Oct3/4+ cells differentiate into cardiac myocytes via age-dependent paracrine mechanisms. Circ Res 2007; 100: e1-e11 [PMID: 17122441 DOI: 10.1161/01. RES.0000253487.02398.85]
96. Xie Z, Koyama T, Suzuki J, Fujii Y, Togashi H, Sawa H, Nagashima K. Coronary reperfusion following ischemia: different expression of bcl-2 and bax proteins, and cardiomyocyte apoptosis. Jpn Heart J 2001; 42: 759-770 [PMID: 11933925]
97. Nishida S, Nagamine H, Tanaka Y, Watanabe G. Protective effect of basic fibroblast growth factor against myocyte death and arrhythmias in acute myocardial infarction in rats. Circ J 2003; 67: 334-339 [PMID: 12655165]
98. Schenke-Layland K, Strem BM, Jordan MC, Deemedio MT, Hedrick MH, Roos KP, Fraser JK, Maclellan WR. Adipose tissuederived cells improve cardiac function following myocardial infarction. J Surg Res 2009; 153: 217-223 [PMID: 18694573 DOI: 10.1016/j.jss.2008.03.019]
99. Estrada R, Li N, Sarojini H, An J, Lee MJ, Wang E. Secretome from mesenchymal stem cells induces angiogenesis via Cyr61. J Cell Physiol 2009; 219: 563-571 [PMID: 19170074 DOI: 10.1002/ jcp.21701]
100. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, Rovner A, Ellis SG, Thomas JD, DiCorleto PE, Topol EJ, Penn MS. Effect of stromal-cell-derived factor 1 on stemcell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003; 362: 697-703 [PMID: 12957092 DOI: 10.1016/ S0140-6736(03)14232-8]
101. Neuss S, Becher E, Wöltje M, Tietze L, Jahnen-Dechent W. Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells 2004; 22: 405-414 [PMID: 15153617 DOI: 10.1634/stemcells.22-3-405]
102. Mourkioti F, Rosenthal N. IGF-1, inflammation and stem cells: interactions during muscle regeneration. Trends Immunol 2005; 26: 535-542 [PMID: 16109502 DOI: 10.1016/j.it.2005.08.002]
103. Linke A, Müller P, Nurzynska D, Casarsa C, Torella D, Nascimbene A, Castaldo C, Cascapera S, Böhm M, Quaini F, Urbanek K, Leri A, Hintze TH, Kajstura J, Anversa P. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci USA 2005; 102: 8966-8971 [PMID: 15951423 DOI: 10.1073/ pnas.0502678102]
104. Xu X, Xu Z, Xu Y, Cui G. Effects of mesenchymal stem cell transplantation on extracellular matrix after myocardial infarction in rats. Coron Artery Dis 2005; 16: 245-255 [PMID: 15915077]
105. Ohnishi S, Sumiyoshi H, Kitamura S, Nagaya N. Mesenchymal stem cells attenuate cardiac fibroblast proliferation and collagen synthesis through paracrine actions. FEBS Lett 2007; 581: 3961-3966 [PMID: 17662720 DOI: 10.1016/j.febslet.2007.07.028]
106. Ohnishi S, Yasuda T, Kitamura S, Nagaya N. Effect of hypoxia on gene expression of bone marrow-derived mesenchymal stem cells and mononuclear cells. Stem Cells 2007; 25: 1166-1177 [PMID: 17289933 DOI: 10.1634/stemcells.2006-0347]
107. Yu Y, Fukuda N, Yao EH, Matsumoto T, Kobayashi N, Suzuki R, Tahira Y, Ueno T, Matsumoto K. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension. Am J Hypertens 2008; 21: 72-77 [PMID: 18091747 DOI: 10.1038/ajh.2007.5]
108. Krupnick AS, Kreisel D, Riha M, Balsara KR, Rosengard BR. Myocardial tissue engineering and regeneration as a therapeutic alternative to transplantation. Curr Top Microbiol Immunol 2004; 280: 139-164 [PMID: 14594210]
109. Brehm M, Stanske B, Strauer BE. Therapeutic potential of stem cells in elderly patients with cardiovascular disease. Exp Gerontol 2008; 43: 1024-1032 [PMID: 18845234 DOI: 10.1016/ j.exger.2008.09.008]
110. Yamada S, Nelson TJ, Behfar A, Crespo-Diaz RJ, Fraidenraich D, Terzic A. Stem cell transplant into preimplantation embryo yields myocardial infarction-resistant adult phenotype. Stem Cells 2009; 27: 1697-1705 [PMID: 19544428 DOI: 10.1002/stem.116]
111. Seidel M, Borczyńska A, Rozwadowska N, Kurpisz M. Cell-based therapy for heart failure: skeletal myoblasts. Cell Transplant 2009; 18: 695-707 [PMID: 19500482 DOI: 10.3727/096368909X470810]
112. LaPar DJ, Kron IL, Yang Z. Stem cell therapy for ischemic heart disease: where are we? Curr Opin Organ Transplant 2009; 14: 79-84 [PMID: 19337151 DOI: 10.1097/MOT.0b013e328320d2e2]
113. Boudoulas KD, Hatzopoulos AK. Cardiac repair and regeneration: the Rubik's cube of cell therapy for heart disease. Dis Model Mech 2009; 2: 344-358 [PMID: 19553696 DOI: 10.1242/dmm.000240]
114. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-1136 [PMID: 3769170]
115. Tang YL, Zhu W, Cheng M, Chen L, Zhang J, Sun T, Kishore R, Phillips MI, Losordo DW, Qin G. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res 2009; 104: 1209-1216 [PMID: 19407239 DOI: 10.1161/ CIRCRESAHA.109.197723]
116. Rosová I, Dao M, Capoccia B, Link D, Nolta JA. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 2008; 26: 2173-2182 [PMID: 18511601 DOI: 10.1634/ stemcells.2007-1104]
117. Kubo M, Li TS, Suzuki R, Shirasawa B, Morikage N, Ohshima M, Qin SL, Hamano K. Hypoxic preconditioning increases survival and angiogenic potency of peripheral blood mononuclear cells via oxidative stress resistance. Am J Physiol Heart Circ Physiol 2008; 294: H590-H595 [PMID: 18156196 DOI: 10.1152/ ajpheart.00856.2007]
118. Haider HKh, Ashraf M. Preconditioning and stem cell survival. J Cardiovasc Transl Res 2010; 3: 89-102 [PMID: 20560023 DOI: 10.1007/s12265-009-9161-2]
119. Hu X, Yu SP, Fraser JL, Lu Z, Ogle ME, Wang JA, Wei L. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg 2008; 135: 799-808 [PMID: 18374759 DOI: 10.1016/j.jtcvs.2007.07.071]
120. Yuan G, Nanduri J, Khan S, Semenza GL, Prabhakar NR. Induction of HIF-1alpha expression by intermittent hypoxia: involvement of NADPH oxidase, Ca2+ signaling, prolyl hydroxylases, and mTOR. J Cell Physiol 2008; 217: 674-685 [PMID: 18651560 DOI: 10.1002/jcp.21537]
121. Nanduri J, Yuan G, Kumar GK, Semenza GL, Prabhakar NR. Transcriptional responses to intermittent hypoxia. Respir Physiol Neurobiol 2008; 164: 277-281 [PMID: 18692603 DOI: 10.1016/ j.resp.2008.07.006]
122. Chau CH, Clavijo CA, Deng HT, Zhang Q, Kim KJ, Qiu Y, Le AD, Ann DK. Etk/Bmx mediates expression of stress-induced adaptive genes VEGF, PAI-1, and iNOS via multiple signaling cascades in different cell systems. Am J Physiol Cell Physiol 2005; 289: C444-C454 [PMID: 15788485 DOI: 10.1152/ajpcell.00410.2004]
123. Cipolleschi MG, D'Ippolito G, Bernabei PA, Caporale R, Nannini R, Mariani M, Fabbiani M, Rossi-Ferrini P, Olivotto M, Dello Sbarba P. Severe hypoxia enhances the formation of erythroid bursts from human cord blood cells and the maintenance of BFU-E in vitro. Exp Hematol 1997; 25: 1187-1194 [PMID: 9328456]
124. Li W, Ma N, Ong LL, Nesselmann C, Klopsch C, Ladilov Y, Furlani D, Piechaczek C, Moebius JM, Lützow K, Lendlein A, Stamm C, Li RK, Steinhoff G. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells 2007; 25: 2118-2127 [PMID: 17478584 DOI: 10.1634/stemcells.2006-0771]
125. Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, Mu H, Melo LG, Pratt RE, Ingwall JS, Dzau VJ. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cellmediated cardiac protection and functional improvement. FASEB J 2006; 20: 661-669 [PMID: 16581974 DOI: 10.1096/fj.05-5211com]
126. Theus MH, Wei L, Cui L, Francis K, Hu X, Keogh C, Yu SP. In vitro hypoxic preconditioning of embryonic stem cells as a strategy of promoting cell survival and functional benefits after transplantation into the ischemic rat brain. Exp Neurol 2008; 210: 656-670 [PMID: 18279854 DOI: 10.1016/j.expneurol.2007.12.020]
127. Heads RJ, Yellon DM, Latchman DS. Differential cytoprotection against heat stress or hypoxia following expression of specific stress protein genes in myogenic cells. J Mol Cell Cardiol 1995; 27: 1669-1678 [PMID: 8523429]
128. Das R, Jahr H, van Osch GJ, Farrell E. The role of hypoxia in bone marrow-derived mesenchymal stem cells: considerations for regenerative medicine approaches. Tissue Eng Part B Rev 2010; 16: 159-168 [PMID: 19698058 DOI: 10.1089/ten.TEB.2009.0296]
129. Akita T, Murohara T, Ikeda H, Sasaki K, Shimada T, Egami K, Imaizumi T. Hypoxic preconditioning augments efficacy of human endothelial progenitor cells for therapeutic neovascularization. Lab Invest 2003; 83: 65-73 [PMID: 12533687]
130. He A, Jiang Y, Gui C, Sun Y, Li J, Wang JA. The antiapoptotic effect of mesenchymal stem cell transplantation on ischemic myocardium is enhanced by anoxic preconditioning. Can J Cardiol 2009; 25: 353-358 [PMID: 19536376]
131. Pendergrass KD, Boopathy AV, Seshadri G, Maiellaro-Rafferty K, Che PL, Brown ME, Davis ME. Acute preconditioning of cardiac progenitor cells with hydrogen peroxide enhances angiogenic pathways following ischemia-reperfusion injury. Stem Cells Dev 2013; 22: 2414-2424 [PMID: 23544670 DOI: 10.1089/ scd.2012.0673]
132. Sharma RK, Zhou Q, Netland PA. Effect of oxidative preconditioning on neural progenitor cells. Brain Res 2008; 1243: 19-26 [PMID: 18761002 DOI: 10.1016/j.brainres.2008.08.025]
133. Zhang J, Chen GH, Wang YW, Zhao J, Duan HF, Liao LM, Zhang XZ, Chen YD, Chen H. Hydrogen peroxide preconditioning enhances the therapeutic efficacy of Wharton's Jelly mesenchymal stem cells after myocardial infarction. Chin Med J (Engl) 2012; 125: 3472-3478 [PMID: 23044308]
134. Su CY, Chong KY, Chen J, Ryter S, Khardori R, Lai CC. A physiologically relevant hyperthermia selectively activates constitutive hsp70 in H9c2 cardiac myoblasts and confers oxidative protection. J Mol Cell Cardiol 1999; 31: 845-855 [PMID: 10329212 DOI: 10.1006/jmcc.1998.0923]
135. Haider HKh, Ashraf M. Strategies to promote donor cell survival: combining preconditioning approach with stem cell transplantation. J Mol Cell Cardiol 2008; 45: 554-566 [PMID: 18561945 DOI: 10.1016/j.yjmcc.2008.05.004]
136. Laflamme MA, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras SK, Reinecke H, Xu C, Hassanipour M, Police S, O'Sullivan C, Collins L, Chen Y, Minami E, Gill EA, Ueno S, Yuan C, Gold J, Murry CE. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007; 25: 1015-1024 [PMID: 17721512 DOI: 10.1038/nbt1327]
137. Laflamme MA, Gold J, Xu C, Hassanipour M, Rosler E, Police S, Muskheli V, Murry CE. Formation of human myocardium in the rat heart from human embryonic stem cells. Am J Pathol 2005; 167: 663-671 [PMID: 16127147 DOI: 10.1016/S0002-9440(10)62041-X]
138. Moloney TC, Hoban DB, Barry FP, Howard L, Dowd E. Kinetics of thermally induced heat shock protein 27 and 70 expression by bone marrow-derived mesenchymal stem cells. Protein Sci 2012; 21: 904-909 [PMID: 22505291 DOI: 10.1002/pro.2077]
139. Feng Y, Huang W, Meng W, Jegga AG, Wang Y, Cai W, Kim HW, Pasha Z, Wen Z, Rao F, Modi RM, Yu X, Ashraf M. Heat shock improves Sca-1+ stem cell survival and directs ischemic cardiomyocytes toward a prosurvival phenotype via exosomal transfer: a critical role for HSF1/miR-34a/HSP70 pathway. Stem Cells 2014; 32: 462-472 [PMID: 24123326 DOI: 10.1002/stem.1571]
140. Kis B, Nagy K, Snipes JA, Rajapakse NC, Horiguchi T, Grover GJ, Busija DW. The mitochondrial K(ATP) channel opener BMS-191095 induces neuronal preconditioning. Neuroreport 2004; 15: 345-349 [PMID: 15076766]
141. Sato T, Li Y, Saito T, Nakaya H. Minoxidil opens mitochondrial K(ATP) channels and confers cardioprotection. Br J Pharmacol 2004; 141: 360-366 [PMID: 14691056 DOI: 10.1038/sj.bjp.0705613]
142. Kicińska A, Szewczyk A. Protective effects of the potassium channel opener-diazoxide against injury in neonatal rat ventricular myocytes. Gen Physiol Biophys 2003; 22: 383-395 [PMID: 14986888]
143. Busija DW, Katakam P, Rajapakse NC, Kis B, Grover G, Domoki F, Bari F. Effects of ATP-sensitive potassium channel activators diazoxide and BMS-191095 on membrane potential and reactive oxygen species production in isolated piglet mitochondria. Brain Res Bull 2005; 66: 85-90 [PMID: 15982523 DOI: 10.1016/j.brainre sbull.2005.03.022]
144. Rajapakse N, Kis B, Horiguchi T, Snipes J, Busija D. Diazoxide pretreatment induces delayed preconditioning in astrocytes against oxygen glucose deprivation and hydrogen peroxide-induced toxicity. J Neurosci Res 2003; 73: 206-214 [PMID: 12836163 DOI: 10.1002/jnr.10657]
145. O'Sullivan JC, Yao XL, Alam H, McCabe JT. Diazoxide, as a postconditioning and delayed preconditioning trigger, increases HSP25 and HSP70 in the central nervous system following combined cerebral stroke and hemorrhagic shock. J Neurotrauma 2007; 24: 532-546 [PMID: 17402858 DOI: 10.1089/neu.2006.0128]
146. Niagara MI, Haider HKh, Jiang S, Ashraf M. Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ Res 2007; 100: 545-555 [PMID: 17234963 DOI: 10.1161/01.RES.0000258460.41160.ef]
147. Ahmad N, Wang Y, Haider KH, Wang B, Pasha Z, Uzun O, Ashraf M. Cardiac protection by mitoKATP channels is dependent on Akt translocation from cytosol to mitochondria during late preconditioning. Am J Physiol Heart Circ Physiol 2006; 290: H2402-H2408 [PMID: 16687609 DOI: 10.1152/ ajpheart.00737.2005]
148. Yang YJ, Qian HY, Huang J, Geng YJ, Gao RL, Dou KF, Yang GS, Li JJ, Shen R, He ZX, Lu MJ, Zhao SH. Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. Eur Heart J 2008; 29: 1578-1590 [PMID: 18456710 DOI: 10.1093/eurheartj/ehn167]
149. Assmus B, Urbich C, Aicher A, Hofmann WK, Haendeler J, Rössig L, Spyridopoulos I, Zeiher AM, Dimmeler S. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 2003; 92: 1049-1055 [PMID: 12676819 DOI: 10.1161/01.RES.0000070067.64040.7C]
150. Spyridopoulos I, Haendeler J, Urbich C, Brummendorf TH, Oh H, Schneider MD, Zeiher AM, Dimmeler S. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 2004; 110: 3136-3142 [PMID: 15520325 DOI: 10.1161/01.CIR.0000142866.50300.EB]
151. Park A, Barrera-Ramirez J, Ranasinghe I, Pilon S, Sy R, Fergusson D, Allan DS. Use of Statins to Augment Progenitor Cell Function in Preclinical and Clinical Studies of Regenerative Therapy: a Systematic Review. Stem Cell Rev 2016; 12: 327-339 [PMID: 26873165 DOI: 10.1007/s12015-016-9647-7]
152. Szeto A, Nation DA, Mendez AJ, Dominguez-Bendala J, Brooks LG, Schneiderman N, McCabe PM. Oxytocin attenuates NADPH-dependent superoxide activity and IL-6 secretion in macrophages and vascular cells. Am J Physiol Endocrinol Metab 2008; 295: E1495-E1501 [PMID: 18940936 DOI: 10.1152/ ajpendo.90718.2008]
153. Paquin J, Danalache BA, Jankowski M, McCann SM, Gutkowska J. Oxytocin induces differentiation of P19 embryonic stem cells to cardiomyocytes. Proc Natl Acad Sci USA 2002; 99: 9550-9555 [PMID: 12093924 DOI: 10.1073/pnas.152302499]
154. Cattaneo MG, Lucci G, Vicentini LM. Oxytocin stimulates in vitro angiogenesis via a Pyk-2/Src-dependent mechanism. Exp Cell Res 2009; 315: 3210-3219 [PMID: 19563802 DOI: 10.1016/ j.yexcr.2009.06.022]
155. Florian M, Jankowski M, Gutkowska J. Oxytocin increases glucose uptake in neonatal rat cardiomyocytes. Endocrinology 2010; 151: 482-491 [PMID: 20008042 DOI: 10.1210/en.2009-0624]
156. Elabd C, Basillais A, Beaupied H, Breuil V, Wagner N, Scheideler M, Zaragosi LE, Massiéra F, Lemichez E, Trajanoski Z, Carle G, Euller-Ziegler L, Ailhaud G, Benhamou CL, Dani C, Amri EZ. Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis. Stem Cells 2008; 26: 2399-2407 [PMID: 18583541 DOI: 10.1634/stemcells.2008-0127]
157. Cattaneo MG, Chini B, Vicentini LM. Oxytocin stimulates migration and invasion in human endothelial cells. Br J Pharmacol 2008; 153: 728-736 [PMID: 18059319 DOI: 10.1038/ sj.bjp.0707609]
158. Cassoni P, Marrocco T, Bussolati B, Allia E, Munaron L, Sapino A, Bussolati G. Oxytocin induces proliferation and migration in immortalized human dermal microvascular endothelial cells and human breast tumor-derived endothelial cells. Mol Cancer Res 2006; 4: 351-359 [PMID: 16778082 DOI: 10.1158/1541-7786. MCR-06-0024]
159. Noiseux N, Borie M, Desnoyers A, Menaouar A, Stevens LM, Mansour S, Danalache BA, Roy DC, Jankowski M, Gutkowska J. Preconditioning of stem cells by oxytocin to improve their therapeutic potential. Endocrinology 2012; 153: 5361-5372 [PMID: 23024264 DOI: 10.1210/en.2012-1402]
160. Wisel S, Khan M, Kuppusamy ML, Mohan IK, Chacko SM, Rivera BK, Sun BC, Hideg K, Kuppusamy P. Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. J Pharmacol Exp Ther 2009; 329: 543-550 [PMID: 19218529 DOI: 10.1124/jpet.109.150839]
161. Cízková D, Rosocha J, Vanický I, Radonák J, Gálik J, Cízek M. Induction of mesenchymal stem cells leads to HSP72 synthesis and higher resistance to oxidative stress. Neurochem Res 2006; 31: 1011-1020 [PMID: 16865557 DOI: 10.1007/s11064-006-9107-x]
162. Imai Y, Adachi Y, Shi M, Shima C, Yanai S, Okigaki M, Yamashima T, Kaneko K, Ikehara S. Caspase inhibitor ZVAD-fmk facilitates engraftment of donor hematopoietic stem cells in intrabone marrow-bone marrow transplantation. Stem Cells Dev 2010; 19: 461-468 [PMID: 19686047 DOI: 10.1089/scd.2009.0251]
163. Yun BG, Matts RL. Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation. Exp Cell Res 2005; 307: 212-223 [PMID: 15922741 DOI: 10.1016/j.yexcr.2005.03.003]
164. Xaymardan M, Cimini M, Fazel S, Weisel RD, Lu WY, Martin U, Harvey RP, Li RK. c-Kit function is necessary for in vitro myogenic differentiation of bone marrow hematopoietic cells. Stem Cells 2009; 27: 1911-1920 [PMID: 19544423 DOI: 10.1002/stem.106]
165. Roussel M, Moreau P, Huynh A, Mary JY, Danho C, Caillot D, Hulin C, Fruchart C, Marit G, Pégourié B, Lenain P, Araujo C, Kolb B, Randriamalala E, Royer B, Stoppa AM, Dib M, Dorvaux V, Garderet L, Mathiot C, Avet-Loiseau H, Harousseau JL, Attal M. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010; 115: 32-37 [PMID: 19884643 DOI: 10.1182/blood-2009-06-229658]
166. Pinna GF, Fiorucci M, Reimund JM, Taquet N, Arondel Y, Muller CD. Celastrol inhibits pro-inflammatory cytokine secretion in Crohn's disease biopsies. Biochem Biophys Res Commun 2004; 322: 778-786 [PMID: 15336532 DOI: 10.1016/j.bbrc.2004.07.186]
167. Li H, Zhang YY, Huang XY, Sun YN, Jia YF, Li D. Beneficial effect of tripterine on systemic lupus erythematosus induced by active chromatin in BALB/c mice. Eur J Pharmacol 2005; 512: 231-237 [PMID: 15840409 DOI: 10.1016/j.ejphar.2005.02.030]
168. Li H, Zhang YY, Tan HW, Jia YF, Li D. Therapeutic effect of tripterine on adjuvant arthritis in rats. J Ethnopharmacol 2008; 118: 479-484 [PMID: 18577440 DOI: 10.1016/j.jep.2008.05.028]
169. Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo C. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuropsyc-hopharmacol Biol Psychiatry 2001; 25: 1341-1357 [PMID: 11513350]
170. Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese «Thunder of God Vine,» is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006; 66: 4758-4765 [PMID: 16651429 DOI: 10.1158/0008-5472.CAN-05-4529]
171. Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG, Sun D. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 2008; 7: 162-170 [PMID: 18202019 DOI: 10.1158/1535-7163.MCT-07-0484]
172. Der Sarkissian S, Cailhier JF, Borie M, Stevens LM, Gaboury L, Mansour S, Hamet P, Noiseux N. Celastrol protects ischaemic myocardium through a heat shock response with up-regulation of haeme oxygenase-1. Br J Pharmacol 2014; 171: 5265-5279 [PMID: 25041185 DOI: 10.1111/bph.12838]
173. Jeong WS, Jun M, Kong AN. Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. Antioxid Redox Signal 2006; 8: 99-106 [PMID: 16487042 DOI: 10.1089/ ars.2006.8.99]
174. Zhang M, An C, Gao Y, Leak RK, Chen J, Zhang F. Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection. Prog Neurobiol 2013; 100: 30-47 [PMID: 23025925 DOI: 10.1016/ j.pneurobio.2012.09.003]
175. Biswas C, Shah N, Muthu M, La P, Fernando AP, Sengupta S, Yang G, Dennery PA. Nuclear heme oxygenase-1 (HO-1) modulates subcellular distribution and activation of Nrf2, impacting metabolic and anti-oxidant defenses. J Biol Chem 2014; 289: 26882-26894 [PMID: 25107906 DOI: 10.1074/jbc.M114.567685]
176. Li N, Alam J, Venkatesan MI, Eiguren-Fernandez A, Schmitz D, Di Stefano E, Slaughter N, Killeen E, Wang X, Huang A, Wang M, Miguel AH, Cho A, Sioutas C, Nel AE. Nrf2 is a key transcription factor that regulates antioxidant defense in macrophages and epithelial cells: protecting against the proinflammatory and oxidizing effects of diesel exhaust chemicals. J Immunol 2004; 173: 3467-3481 [PMID: 15322212]
177. Baird NA, Turnbull DW, Johnson EA. Induction of the heat shock pathway during hypoxia requires regulation of heat shock factor by hypoxia-inducible factor-1. J Biol Chem 2006; 281: 38675-38681 [PMID: 17040902 DOI: 10.1074/jbc.M608013200]
178. Zhang T, Li Y, Yu Y, Zou P, Jiang Y, Sun D. Characterization of celastrol to inhibit hsp90 and cdc37 interaction. J Biol Chem 2009; 284: 35381-35389 [PMID: 19858214 DOI: 10.1074/jbc. M109.051532]
179. Seo WY, Goh AR, Ju SM, Song HY, Kwon DJ, Jun JG, Kim BC, Choi SY, Park J. Celastrol induces expression of heme oxygenase-1 through ROS/Nrf2/ARE signaling in the HaCaT cells. Biochem Biophys Res Commun 2011; 407: 535-540 [PMID: 21414301 DOI: 10.1016/j.bbrc.2011.03.053]
180. Shintani S, Kusano K, Ii M, Iwakura A, Heyd L, Curry C, Wecker A, Gavin M, Ma H, Kearney M, Silver M, Thorne T, Murohara T, Losordo DW. Synergistic effect of combined intramyocardial CD34+ cells and VEGF2 gene therapy after MI. Nat Clin Pract Cardiovasc Med 2006; 3 Suppl 1: S123-S128 [PMID: 16501618 DOI: 10.1038/ncpcardio0430]
181. Elmadbouh I, Haider HKh, Jiang S, Idris NM, Lu G, Ashraf M. Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium. J Mol Cell Cardiol 2007; 42: 792-803 [PMID: 17350033 DOI: 10.1016/j.yjmcc.2007.02.001]
182. Lataillade JJ, Domenech J, Le Bousse-Kerdilès MC. Stromal cellderived factor-1 (SDF-1)CXCR4 couple plays multiple roles on haematopoietic progenitors at the border between the old cytokine and new chemokine worlds: survival, cell cycling and trafficking. Eur Cytokine Netw 2004; 15: 177-188 [PMID: 15542441]
183. Shyu WC, Lin SZ, Yen PS, Su CY, Chen DC, Wang HJ, Li H. Stromal cell-derived factor-1 alpha promotes neuroprotection, angiogenesis, and mobilization/homing of bone marrow-derived cells in stroke rats. J Pharmacol Exp Ther 2008; 324: 834-849 [PMID: 18029549 DOI: 10.1124/jpet.107.127746]
184. Zemani F, Silvestre JS, Fauvel-Lafeve F, Bruel A, Vilar J, Bieche I, Laurendeau I, Galy-Fauroux I, Fischer AM, Boisson-Vidal C. Ex vivo priming of endothelial progenitor cells with SDF-1 before transplantation could increase their proangiogenic potential. Arterioscler Thromb Vasc Biol 2008; 28: 644-650 [PMID: 18239152 DOI: 10.1161/ATVBAHA.107.160044]
185. Pasha Z, Wang Y, Sheikh R, Zhang D, Zhao T, Ashraf M. Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc Res 2008; 77: 134-142 [PMID: 18006467 DOI: 10.1093/cvr/ cvm025]
186. Lu G, Haider HK, Jiang S, Ashraf M. Sca-1+ stem cell survival and engraftment in the infarcted heart: dual role for preconditioning-induced connexin-43. Circulation 2009; 119: 2587-2596 [PMID: 19414636 DOI: 10.1161/CIRCULATIONAHA.108.827691]
187. Weber-Nordt RM, Henschler R, Schott E, Wehinger J, Behringer D, Mertelsmann R, Finke J. Interleukin-10 increases Bcl-2 expression and survival in primary human CD34+ hematopoietic progenitor cells. Blood 1996; 88: 2549-2558 [PMID: 8839847]
188. Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, Genrich K, Mehrotra S, Setty S, Smith B, Bartholomew A. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 2008; 38: 1745-1755 [PMID: 18493986 DOI: 10.1002/eji.200738129]
189. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-150 [PMID: 18371435 DOI: 10.1016/ j.stem.2007.11.014]
190. English K, Barry FP, Field-Corbett CP, Mahon BP. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 2007; 110: 91-100 [PMID: 17507101 DOI: 10.1016/j.imlet.2007.04.001]
191. Dzau VJ, Gnecchi M, Pachori AS. Enhancing stem cell therapy through genetic modification. J Am Coll Cardiol 2005; 46: 1351-1353 [PMID: 16198854 DOI: 10.1016/j.jacc.2005.07.023]
192. Matsumoto R, Omura T, Yoshiyama M, Hayashi T, Inamoto S, Koh KR, Ohta K, Izumi Y, Nakamura Y, Akioka K, Kitaura Y, Takeuchi K, Yoshikawa J. Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler Thromb Vasc Biol 2005; 25: 1168-1173 [PMID: 15831811 DOI: 10.1161/01. ATV.0000165696.25680.ce]
193. Yau TM, Kim C, Ng D, Li G, Zhang Y, Weisel RD, Li RK. Increasing transplanted cell survival with cell-based angiogenic gene therapy. Ann Thorac Surg 2005; 80: 1779-1786 [PMID: 16242455 DOI: 10.1016/j.athoracsur.2005.04.079]
194. Kanemitsu N, Tambara K, Premaratne GU, Kimura Y, Tomita S, Kawamura T, Hasegawa K, Tabata Y, Komeda M. Insulin-like growth factor-1 enhances the efficacy of myoblast transplantation with its multiple functions in the chronic myocardial infarction rat model. J Heart Lung Transplant 2006; 25: 1253-1262 [PMID: 17045939 DOI: 10.1016/j.healun.2006.05.012]
195. Kofidis T, de Bruin JL, Yamane T, Balsam LB, Lebl DR, Swijnenburg RJ, Tanaka M, Weissman IL, Robbins RC. Insulin-like growth factor promotes engraftment, differentiation, and functional improvement after transfer of embryonic stem cells for myocardial restoration. Stem Cells 2004; 22: 1239-1245 [PMID: 15579642 DOI: 10.1634/stemcells.2004-0127]
196. Liu TB, Fedak PW, Weisel RD, Yasuda T, Kiani G, Mickle DA, Jia ZQ, Li RK. Enhanced IGF-1 expression improves smooth muscle cell engraftment after cell transplantation. Am J Physiol Heart Circ Physiol 2004; 287: H2840-H2849 [PMID: 15331370 DOI: 10.1152/ ajpheart.00439.2004]
197. Haider HKh, Jiang S, Idris NM, Ashraf M. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. Circ Res 2008; 103: 1300-1308 [PMID: 18948617 DOI: 10.1161/CIRCRESAHA.108.186742]
198. Duan HF, Wu CT, Wu DL, Lu Y, Liu HJ, Ha XQ, Zhang QW, Wang H, Jia XX, Wang LS. Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Mol Ther 2003; 8: 467-474 [PMID: 12946320]
199. Hattan N, Warltier D, Gu W, Kolz C, Chilian WM, Weihrauch D. Autologous vascular smooth muscle cell-based myocardial gene therapy to induce coronary collateral growth. Am J Physiol Heart Circ Physiol 2004; 287: H488-H493 [PMID: 15277192 DOI: 10.1152/ajpheart.00145.2004]
200. Miyagawa S, Sawa Y, Taketani S, Kawaguchi N, Nakamura T, Matsuura N, Matsuda H. Myocardial regeneration therapy for heart failure: hepatocyte growth factor enhances the effect of cellular cardiomyoplasty. Circulation 2002; 105: 2556-2561 [PMID: 12034665]
201. Murry CE, Kay MA, Bartosek T, Hauschka SD, Schwartz SM. Muscle differentiation during repair of myocardial necrosis in rats via gene transfer with MyoD. J Clin Invest 1996; 98: 2209-2217 [PMID: 8941636 DOI: 10.1172/JCI119030]
202. Payne TR, Oshima H, Okada M, Momoi N, Tobita K, Keller BB, Peng H, Huard J. A relationship between vascular endothelial growth factor, angiogenesis, and cardiac repair after muscle stem cell transplantation into ischemic hearts. J Am Coll Cardiol 2007; 50: 1677-1684 [PMID: 17950150 DOI: 10.1016/j.jacc.2007.04.100]
203. Yau TM, Fung K, Weisel RD, Fujii T, Mickle DA, Li RK. Enhanced myocardial angiogenesis by gene transfer with transplanted cells. Circulation 2001; 104: I218-I222 [PMID: 11568059]
204. Yau TM, Li G, Weisel RD, Reheman A, Jia ZQ, Mickle DA, Li RK. Vascular endothelial growth factor transgene expression in cell-transplanted hearts. J Thorac Cardiovasc Surg 2004; 127: 1180-1187 [PMID: 15052220 DOI: 10.1016/j.jtcvs.2003.09.052]
205. Zhang M, Mal N, Kiedrowski M, Chacko M, Askari AT, Popovic ZB, Koc ON, Penn MS. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J 2007; 21: 3197-3207 [PMID: 17496162 DOI: 10.1096/fj.06-6558com]
206. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998; 273: 13313-13316 [PMID: 9582377]
207. Das H, George JC, Joseph M, Das M, Abdulhameed N, Blitz A, Khan M, Sakthivel R, Mao HQ, Hoit BD, Kuppusamy P, Pompili VJ. Stem cell therapy with overexpressed VEGF and PDGF genes improves cardiac function in a rat infarct model. PLoS One 2009; 4: e7325 [PMID: 19809493 DOI: 10.1371/journal.pone.0007325]
208. Markel TA, Wang Y, Herrmann JL, Crisostomo PR, Wang M, Novotny NM, Herring CM, Tan J, Lahm T, Meldrum DR. VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function. Am J Physiol Heart Circ Physiol 2008; 295: H2308-H2314 [PMID: 18849336 DOI: 10.1152/ ajpheart.00565.2008]
209. Haider HK, Elmadbouh I, Jean-Baptiste M, Ashraf M. Nonviral vector gene modification of stem cells for myocardial repair. Mol Med 2008; 14: 79-86 [PMID: 17985003 DOI: 10.2119/2007-00092. Haider]
210. Liu LX, Lu H, Luo Y, Date T, Belanger AJ, Vincent KA, Akita GY, Goldberg M, Cheng SH, Gregory RJ, Jiang C. Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem Biophys Res Commun 2002; 291: 908-914 [PMID: 11866451 DOI: 10.1006/bbrc.2002.6551]
211. Zou D, Zhang Z, He J, Zhang K, Ye D, Han W, Zhou J, Wang Y, Li Q, Liu X, Zhang X, Wang S, Hu J, Zhu C, Zhang W, zhou Y, Fu H, Huang Y, Jiang X. Blood vessel formation in the tissue-engineered bone with the constitutively active form of HIF-1α mediated BMSCs. Biomaterials 2012; 33: 2097-2108 [PMID: 22172336 DOI: 10.1016/j.biomaterials.2011.11.053]
212. Razban V, Lotfi AS, Soleimani M, Ahmadi H, Massumi M, Khajeh S, Ghaedi M, Arjmand S, Najavand S, Khoshdel A. HIF-1α Overexpression Induces Angiogenesis in Mesenchymal Stem Cells. Biores Open Access 2012; 1: 174-183 [PMID: 23514846 DOI: 10.1089/biores.2012.9905]
213. Phillips MI, Tang YL. Genetic modification of stem cells for transplantation. Adv Drug Deliv Rev 2008; 60: 160-172 [PMID: 18031863 DOI: 10.1016/j.addr.2007.08.035]
214. Chachques JC, Trainini JC, Lago N, Cortes-Morichetti M, Schussler O, Carpentier A. Myocardial Assistance by Grafting a New Bioartificial Upgraded Myocardium (MAGNUM trial): clinical feasibility study. Ann Thorac Surg 2008; 85: 901-908 [PMID: 18291168 DOI: 10.1016/j.athoracsur.2007.10.052]
215. Song H, Kwon K, Lim S, Kang SM, Ko YG, Xu Z, Chung JH, Kim BS, Lee H, Joung B, Park S, Choi D, Jang Y, Chung NS, Yoo KJ, Hwang KC. Transfection of mesenchymal stem cells with the FGF-2 gene improves their survival under hypoxic conditions. Mol Cells 2005; 19: 402-407 [PMID: 15995358]
216. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, Noiseux N, Zhang L, Pratt RE, Ingwall JS, Dzau VJ. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005; 11: 367-368 [PMID: 15812508 DOI: 10.1038/nm0405-367]
217. Gnecchi M, He H, Melo LG, Noiseaux N, Morello F, de Boer RA, Zhang L, Pratt RE, Dzau VJ, Ingwall JS. Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction. Stem Cells 2009; 27: 971-979 [PMID: 19353525 DOI: 10.1002/stem.12]
218. Shujia J, Haider HK, Idris NM, Lu G, Ashraf M. Stable therapeutic effects of mesenchymal stem cell-based multiple gene delivery for cardiac repair. Cardiovasc Res 2008; 77: 525-533 [PMID: 18032392 DOI: 10.1093/cvr/cvm077]
219. Melo LG, Agrawal R, Zhang L, Rezvani M, Mangi AA, Ehsan A, Griese DP, Dell'Acqua G, Mann MJ, Oyama J, Yet SF, Layne MD, Perrella MA, Dzau VJ. Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation 2002; 105: 602-607 [PMID: 11827926]
220. Vulapalli SR, Chen Z, Chua BH, Wang T, Liang CS. Cardioselective overexpression of HO-1 prevents I/R-induced cardiac dysfunction and apoptosis. Am J Physiol Heart Circ Physiol 2002; 283: H688-H694 [PMID: 12124217 DOI: 10.1152/ajpheart.00133.2002]
221. Tang YL, Tang Y, Zhang YC, Qian K, Shen L, Phillips MI. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol 2005; 46: 1339-1350 [PMID: 16198853 DOI: 10.1016/ j.jacc.2005.05.079]
222. Snoeckx LH, Cornelussen RN, Van Nieuwenhoven FA, Reneman RS, Van Der Vusse GJ. Heat shock proteins and cardiovascular pathophysiology. Physiol Rev 2001; 81: 1461-1497 [PMID: 11581494]
223. Hutter MM, Sievers RE, Barbosa V, Wolfe CL. Heat-shock protein induction in rat hearts. A direct correlation between the amount of heat-shock protein induced and the degree of myocardial protection. Circulation 1994; 89: 355-360 [PMID: 8281669]
224. Jayakumar J, Suzuki K, Khan M, Smolenski RT, Farrell A, Latif N, Raisky O, Abunasra H, Sammut IA, Murtuza B, Amrani M, Yacoub MH. Gene therapy for myocardial protection: transfection of donor hearts with heat shock protein 70 gene protects cardiac function against ischemia-reperfusion injury. Circulation 2000; 102: III302-III306 [PMID: 11082405]
225. Okubo S, Wildner O, Shah MR, Chelliah JC, Hess ML, Kukreja RC. Gene transfer of heat-shock protein 70 reduces infarct size in vivo after ischemia/reperfusion in the rabbit heart. Circulation 2001; 103: 877-881 [PMID: 11171798]
226. Kabakov AE, Budagova KR, Bryantsev AL, Latchman DS. Heat shock protein 70 or heat shock protein 27 overexpressed in human endothelial cells during posthypoxic reoxygenation can protect from delayed apoptosis. Cell Stress Chaperones 2003; 8: 335-347 [PMID: 15115286]
227. Kim I, Kim HG, Moon SO, Chae SW, So JN, Koh KN, Ahn BC, Koh GY. Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion. Circ Res 2000; 86: 952-959 [PMID: 10807867]
228. DeBusk LM, Hallahan DE, Lin PC. Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway. Exp Cell Res 2004; 298: 167-177 [PMID: 15242771 DOI: 10.1016/ j.yexcr.2004.04.013]
229. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos GD, Isner JM. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 1998; 83: 233-240 [PMID: 9710115]
230. Jiang S, Haider HKh, Idris NM, Salim A, Ashraf M. Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair. Circ Res 2006; 99: 776-784 [PMID: 16960098 DOI: 10.1161/01.RES.0000244687.97719.4f]
231. Song H, Chang W, Lim S, Seo HS, Shim CY, Park S, Yoo KJ, Kim BS, Min BH, Lee H, Jang Y, Chung N, Hwang KC. Tissue transglutaminase is essential for integrin-mediated survival of bone marrow-derived mesenchymal stem cells. Stem Cells 2007; 25: 1431-1438 [PMID: 17347495 DOI: 10.1634/stemcells.2006-0467]
232. Persad S, Attwell S, Gray V, Mawji N, Deng JT, Leung D, Yan J, Sanghera J, Walsh MP, Dedhar S. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 2001; 276: 27462-27469 [PMID: 11313365 DOI: 10.1074/jbc.M102940200]
233. Akimov SS, Krylov D, Fleischman LF, Belkin AM. Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J Cell Biol 2000; 148: 825-838 [PMID: 10684262]
234. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418: 41-49 [PMID: 12077603 DOI: 10.1038/ nature00870]
235. Schwartz MA, Schaller MD, Ginsberg MH. Integrins: emerging paradigms of signal transduction. Annu Rev Cell Dev Biol 1995; 11: 549-599 [PMID: 8689569 DOI: 10.1146/annurev.cb.11.1-10195.003001]
236. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science 1995; 268: 233-239 [PMID: 7716514]
237. White DE, Cardiff RD, Dedhar S, Muller WJ. Mammary epithelialspecific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene 2001; 20: 7064-7072 [PMID: 11704830 DOI: 10.1038/sj.onc.1204910]
238. Cho HJ, Youn SW, Cheon SI, Kim TY, Hur J, Zhang SY, Lee SP, Park KW, Lee MM, Choi YS, Park YB, Kim HS. Regulation of endothelial cell and endothelial progenitor cell survival and vasculogenesis by integrin-linked kinase. Arterioscler Thromb Vasc Biol 2005; 25: 1154-1160 [PMID: 15802621 DOI: 10.1161/01. ATV.0000164312.20008.93]
239. Song H, Song BW, Cha MJ, Choi IG, Hwang KC. Modification of mesenchymal stem cells for cardiac regeneration. Expert Opin Biol Ther 2010; 10: 309-319 [PMID: 20132054 DOI: 10.1517/14712590 903455997]
240. Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 2005; 433: 760-764 [PMID: 15716955 DOI: 10.1038/nature03260]
241. Sharpless NE, DePinho RA. How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol 2007; 8: 703-713 [PMID: 17717515 DOI: 10.1038/nrm2241]
242. Chimenti C, Kajstura J, Torella D, Urbanek K, Heleniak H, Colussi C, Di Meglio F, Nadal-Ginard B, Frustaci A, Leri A, Maseri A, Anversa P. Senescence and death of primitive cells and myocytes lead to premature cardiac aging and heart failure. Circ Res 2003; 93: 604-613 [PMID: 12958145 DOI: 10.1161/01. RES.0000093985.76901.AF]
243. Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 2010; 7: 150-161 [PMID: 20682444 DOI: 10.1016/ j.stem.2010.07.007]
244. Sanada F, Kim J, Czarna A, Chan NY, Signore S, Ogórek B, Isobe K, Wybieralska E, Borghetti G, Pesapane A, Sorrentino A, Mangano E, Cappetta D, Mangiaracina C, Ricciardi M, Cimini M, Ifedigbo E, Perrella MA, Goichberg P, Choi AM, Kajstura J, Hosoda T, Rota M, Anversa P, Leri A. c-Kit-positive cardiac stem cells nested in hypoxic niches are activated by stem cell factor reversing the aging myopathy. Circ Res 2014; 114: 41-55 [PMID: 24170267 DOI: 10.1161/CIRCRESAHA.114.302500]
245. Hekimi S, Guarente L. Genetics and the specificity of the aging process. Science 2003; 299: 1351-1354 [PMID: 12610295 DOI: 10.1126/science.1082358]
246. Kajstura J, Gurusamy N, Ogórek B, Goichberg P, Clavo-Rondon C, Hosoda T, D'Amario D, Bardelli S, Beltrami AP, Cesselli D, Bussani R, del Monte F, Quaini F, Rota M, Beltrami CA, Buchholz BA, Leri A, Anversa P. Myocyte turnover in the aging human heart. Circ Res 2010; 107: 1374-1386 [PMID: 21088285 DOI: 10.1161/ CIRCRESAHA.110.231498]
247. Chidgey A, Dudakov J, Seach N, Boyd R. Impact of niche aging on thymic regeneration and immune reconstitution. Semin Immunol 2007; 19: 331-340 [PMID: 18024073 DOI: 10.1016/ j.smim.2007.10.006]
248. Fan M, Chen W, Liu W, Du GQ, Jiang SL, Tian WC, Sun L, Li RK, Tian H. The effect of age on the efficacy of human mesenchymal stem cell transplantation after a myocardial infarction. Rejuvenation Res 2010; 13: 429-438 [PMID: 20583954 DOI: 10.1089/rej.2009.0986]
249. Kan CD, Li SH, Weisel RD, Zhang S, Li RK. Recipient age determines the cardiac functional improvement achieved by skeletal myoblast transplantation. J Am Coll Cardiol 2007; 50: 1086-1092 [PMID: 17825720 DOI: 10.1016/j.jacc.2007.06.009]
250. Zhang H, Fazel S, Tian H, Mickle DA, Weisel RD, Fujii T, Li RK. Increasing donor age adversely impacts beneficial effects of bone marrow but not smooth muscle myocardial cell therapy. Am J Physiol Heart Circ Physiol 2005; 289: H2089-H2096 [PMID: 16219813 DOI: 10.1152/ajpheart.00019.2005]
251. Zhuo Y, Li SH, Chen MS, Wu J, Kinkaid HY, Fazel S, Weisel RD, Li RK. Aging impairs the angiogenic response to ischemic injury and the activity of implanted cells: combined consequences for cell therapy in older recipients. J Thorac Cardiovasc Surg 2010; 139: 1286-1294, 1294.e1-e2 [PMID: 19931095 DOI: 10.1016/ j.jtcvs.2009.08.052]
252. Dimmeler S, Leri A. Aging and disease as modifiers of efficacy of cell therapy. Circ Res 2008; 102: 1319-1330 [PMID: 18535269 DOI: 10.1161/CIRCRESAHA.108.175943]
253. Cesselli D, Beltrami AP, D'Aurizio F, Marcon P, Bergamin N, Toffoletto B, Pandolfi M, Puppato E, Marino L, Signore S, Livi U, Verardo R, Piazza S, Marchionni L, Fiorini C, Schneider C, Hosoda T, Rota M, Kajstura J, Anversa P, Beltrami CA, Leri A. Effects of age and heart failure on human cardiac stem cell function. Am J Pathol 2011; 179: 349-366 [PMID: 21703415 DOI: 10.1016/ j.ajpath.2011.03.036]
254. Li SH, Sun Z, Brunt KR, Shi X, Chen MS, Weisel RD, Li RK. Reconstitution of aged bone marrow with young cells repopulates cardiac-resident bone marrow-derived progenitor cells and prevents cardiac dysfunction after a myocardial infarction. Eur Heart J 2013; 34: 1157-1167 [PMID: 22507976 DOI: 10.1093/eurheartj/ehs072]
255. Sahin E, Depinho RA. Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature 2010; 464: 520-528 [PMID: 20336134 DOI: 10.1038/nature08982]
256. Edwards MG, Anderson RM, Yuan M, Kendziorski CM, Weindruch R, Prolla TA. Gene expression profiling of aging reveals activation of a p53-mediated transcriptional program. BMC Genomics 2007; 8: 80 [PMID: 17381838 DOI: 10.1186/1471-2164-8-80]
257. Ludke A, Li RK, Weisel RD. The rejuvenation of aged stem cells for cardiac repair. Can J Cardiol 2014; 30: 1299-1306 [PMID: 25092405 DOI: 10.1016/j.cjca.2014.03.021]
258. Mohsin S, Khan M, Nguyen J, Alkatib M, Siddiqi S, Hariharan N, Wallach K, Monsanto M, Gude N, Dembitsky W, Sussman MA. Rejuvenation of human cardiac progenitor cells with Pim-1 kinase. Circ Res 2013; 113: 1169-1179 [PMID: 24044948 DOI: 10.1161/ CIRCRESAHA.113.302302]
259. Mohsin S, Khan M, Toko H, Bailey B, Cottage CT, Wallach K, Nag D, Lee A, Siddiqi S, Lan F, Fischer KM, Gude N, Quijada P, Avitabile D, Truffa S, Collins B, Dembitsky W, Wu JC, Sussman MA. Human cardiac progenitor cells engineered with Pim-I kinase enhance myocardial repair. J Am Coll Cardiol 2012; 60: 1278-1287 [PMID: 22841153 DOI: 10.1016/j.jacc.2012.04.047]
260. Bachmann M, Möröy T. The serine/threonine kinase Pim-1. Int J Biochem Cell Biol 2005; 37: 726-730 [PMID: 15694833 DOI: 10.1016/j.biocel.2004.11.005]
261. Muraski JA, Rota M, Misao Y, Fransioli J, Cottage C, Gude N, Esposito G, Delucchi F, Arcarese M, Alvarez R, Siddiqi S, Emmanuel GN, Wu W, Fischer K, Martindale JJ, Glembotski CC, Leri A, Kajstura J, Magnuson N, Berns A, Beretta RM, Houser SR, Schaefer EM, Anversa P, Sussman MA. Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med 2007; 13: 1467-1475 [PMID: 18037896 DOI: 10.1038/nm1671]
262. Borillo GA, Mason M, Quijada P, Völkers M, Cottage C, McGregor M, Din S, Fischer K, Gude N, Avitabile D, Barlow S, Alvarez R, Truffa S, Whittaker R, Glassy MS, Gustafsson AB, Miyamoto S, Glembotski CC, Gottlieb RA, Brown JH, Sussman MA. Pim-1 kinase protects mitochondrial integrity in cardiomyocytes. Circ Res 2010; 106: 1265-1274 [PMID: 20203306 DOI: 10.1161/ CIRCRESAHA.109.212035]
263. Brunt KR, Zhang Y, Mihic A, Li M, Li SH, Xue P, Zhang W, Basmaji S, Tsang K, Weisel RD, Yau TM, Li RK. Role of WNT/ β-catenin signaling in rejuvenating myogenic differentiation of aged mesenchymal stem cells from cardiac patients. Am J Pathol 2012; 181: 2067-2078 [PMID: 23026201 DOI: 10.1016/j.ajpath.2012.08.021]